Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.61 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RHOA | P61586 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27635203 | 0.84 | AKR1C3 (0.63) | AKR1C3AKR1C2MEN1KMT2ARHOA | |
| SCHEMBL18552696 | 0.84 | POLB (0.68) | ALDH1A1HSD17B10MAPTTSHRSMN1; SMN2 | |
| SCHEMBL873032 | 0.83 | AKR1C3 (0.61) | AKR1C3AKR1C2MEN1KMT2AALDH1A1 | |
| SCHEMBL10586175 | 0.82 | AKR1C3 (0.75) | AKR1C3AKR1C2MEN1KMT2ARHOA | |
| SCHEMBL3210538 | 0.81 | ALDH1A1 (0.50) | AKR1C3AKR1C2CA12CA1CA2 | |
| SCHEMBL3121096 | 0.81 | MEN1 (0.56) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL25717164 | 0.80 | AKR1C3 (0.72) | AKR1C3AKR1C2MEN1KMT2ARHOA | |
| SCHEMBL23173510 | 0.80 | AKR1C3 (0.58) | AKR1C3AKR1C2MEN1KMT2ARHOA | |
| SCHEMBL6325442 | 0.80 | AKR1C3 (0.58) | AKR1C3SMN1; SMN2HPGD | |
| SCHEMBL8686732 | 0.80 | AKR1C3 (0.58) | AKR1C3AKR1C2MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4166557-B1 | INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-12441733-B2 | Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2025-10-14 | — | — | US | disclosed |
| WO-2025076284-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| EP-4467549-A2 | INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | Novartis AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| CN-118754858-A | N- (3- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) phenyl) benzamide derivatives | 诺华股份有限公司 | 2024-10-11 | — | — | CN | disclosed |
| EP-4428130-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-09-11 | — | — | EP | disclosed |
| CN-118159532-A | Compound with BTK protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240158399-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | NOVARTIS AG (CH) | 2024-05-16 | — | — | US | disclosed |
| CN-111936498-B | N- (3- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) phenyl) benzamide derivatives | 诺华股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-114641473-A | BRD9 bifunctional degradation agent and use method thereof | 诺华股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| WO-2021058017-A1 | DEGRADATION OF ANDROGEN RECEPTOR (AR) BY CONJUGATION OF AR ANTAGONISTS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021055295-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055295-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| EP-3774804-A1 | N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | Novartis AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-20210002285-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | NOVARTIS PHARMA AG (CH) | 2021-01-07 | — | — | US | disclosed |
| CN-111936498-A | N- (3- (7H-pyrrolo [2,3-d ] pyrimidin-4-yl) phenyl) benzamide derivatives | 诺华股份有限公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019186343-A1 | N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2019-10-03 | — | — | WO | disclosed |
| US-6479436-B1 | SUCH AS 2-(8-BROMOQUINOLIN-5-YL)CARBONYL-1,3-CYCLOHEXANEDIONE | BASF AKTIENGESELLSCHAFT (DE) | 2002-11-12 | — | — | US | disclosed |
| US-6262074-B1 | 4-Hetaroylpyrazol derivatives and the use thereof as herbicides | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158399-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | PAH, REN, PKD1 | AKR1C3 1115/4885AKR1C2 943/4885CA12 3811/4885 |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | AKR1C3 4392/4885AKR1C2 4394/4885CA12 3885/4885 |
| US-12441733-B2 | Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors | BTK, ABL1, LYN | AKR1C3 3857/4885AKR1C2 3566/4885CA12 3713/4885 |
| US-20210002285-A1 | N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide Derivatives | PAH, PARK7, PKD1 | AKR1C3 1229/4885AKR1C2 1014/4885CA12 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.